Immatics Announces $150 Million Underwritten Offering
Immatics N.V., a clinical-stage biopharmaceutical company focused on precision targeting of PRAME in cancer therapies, announced a $150 million underwritten offering of ordinary shares and pre-funded warrants. The proceeds will support its clinical programs involving TCR T-cell therapies and bispecifics. The offering is expected to close by August …